SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
AMENDMENT NO. 1
Under the Securities Exchange Act of 1934
CORTECH, INC.
----------------------------
(Name of Issuer)
Common Stock par value $.002 per share
- ---------------------------------------------------------------------------
(Title of Class of Securities)
22051J 10 0
-----------------
(CUSIP Number)
Rebecca R. Tilden,Esq.
Vice President and Secretary, Hoechst Marion Roussel, Inc.
Vice President and Assistant Secretary, HMR Pharma, Inc.
10236 Marion Park Drive
Kansas City, Missouri 64137-1405
(816) 966-4000
- ---------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
October 7, 1997
-------------------------------------------------------
(Date of Event Which Requires Filing of This Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is
filing this schedule because of Rule 13d-1(b)(3) or (4), check the
following box. [ ]
Page 1 of 5
There is no Exhibit Index
<PAGE> 2
CUSIP No. 22051J 10 0
___________________________________________________________________________
1) Name of Reporting Person and its Hoechst Marion Roussel, Inc.
I.R.S. Identification Number 44-0565557
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,119,333*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,119,333*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,119,333*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 11.1%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes 562,576 shares that may be acquired upon exercise of stock
purchase warrants.
<PAGE> 3
CUSIP No. 22051J 10 0
___________________________________________________________________________
1) Name of Reporting Person and its HMR Pharma, Inc.
I.R.S. Identification Number 43-1769328
___________________________________________________________________________
2) Check the Appropriate Box if (a)[ ]
a Member of a Group (b)[ ]
___________________________________________________________________________
3) SEC Use Only
___________________________________________________________________________
4) Source of Funds Not applicable
___________________________________________________________________________
5) Check Box if Disclosure of Legal [ ]
Proceedings is Required Pursuant
to Items 2(d) or 2(e)
___________________________________________________________________________
6) Citizenship or Place of Organization Delaware
___________________________________________________________________________
7) Sole Voting Power 2,119,333*
Number of ____________________________________________________________
Shares
Beneficially 8) Shared Voting Power 0
Owned by ____________________________________________________________
Each
Reporting 9) Sole Dispositive Power 2,119,333*
Person With ____________________________________________________________
10) Shared Dispositive Power 0
___________________________________________________________________________
11) Aggregate Amount Beneficially Owned 2,119,333*
by Each Reporting Person
___________________________________________________________________________
12) Check Box If the Aggregate Amount [ ]
in Row (11) Excludes Certain Shares
___________________________________________________________________________
13) Percent of Class Represented 11.1%
by Amount in Row (11)
___________________________________________________________________________
14) Type of Reporting Person CO
___________________________________________________________________________
* Includes 562,576 shares that may be acquired upon exercise of stock
purchase warrants.
<PAGE> 4
This Statement on Schedule 13D (the "Schedule 13D") with respect to
the Common Stock of Cortech, Inc. (the "Issuer"), is filed jointly by
Hoechst Marion Roussel, Inc., a Delaware corporation ("HMRI"), and HMR
Pharma, Inc., a Delaware corporation ("Pharma"), to report a change of
information under Item 4 hereof. The filing of this Statement on behalf of
Pharma shall not be construed as an admission that Pharma is, for the
purposes of Section 13(d) of the Securities Exchange Act of 1934, the
beneficial owner of any securities covered by this Statement.
ITEM 4. PURPOSE OF TRANSACTION.
- ------- -----------------------
Paragraph (a) of Item 4 is amended to read as follows.
(a) HMRI has received an offer to purchase its shares of the Issuer's
Common Stock and has determined to accept the offer or, if the transaction
is not consummated, to dispose of such shares in open market transactions
from time to time or in other transactions as and when opportunities arise.
<PAGE> 5
SIGNATURES
----------
After reasonable inquiry and to the best of their knowledge and
belief, the undersigned certify that the information set forth in this
statement is true, complete and correct.
HOECHST MARION ROUSSEL, INC.
Date: October 7, 1997 By: /s/ Pierre Legault
Vice President and
Chief Financial Officer
HMR PHARMA, INC.
Date: October 7, 1997 By: /s/ Rebecca R. Tilden
Vice President and
Assistant Secretary
